Mineralys Therapeutics, Inc. MLYS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$39.34M-22.0% | -$32.23M+12.7% | -$36.93M+14.7% | -$43.27M-2.5% | -$42.21M+13.8% | ||
| $6K-53.8% | $13K-13.3% | $15K-6.3% | $16K+6.7% | $15K0.0% | ||
| $6.55M+23.9% | $5.29M-9.5% | $5.84M+28.3% | $4.55M+24.9% | $3.65M+16.3% | ||
| -$39.47M-4.2% | -$37.89M-31.2% | -$28.87M+4.3% | -$30.17M+33.7% | -$45.49M+31.9% | ||
| -$44.94M+56.6% | -$103.49M+31.2% | -$150.51M-251% | -$42.88M+53.8% | -$92.88M-211% | ||
| $24.27M-74.9% | $96.7M-67.2% | $295.19M+2,903% | $9.83M-94.8% | $189.28M+210,210% | ||
| -$60.14M— | —— | $115.81M+283% | -$63.22M-224% | $50.92M+203% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Mineralys Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.